Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03051659
Recruitment Status : Active, not recruiting
First Posted : February 14, 2017
Last Update Posted : April 28, 2020
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Sara Tolaney, Dana-Farber Cancer Institute